Drugs /

emb-01

Back to Drugs List

Overview

Clinical Trials

View Clinical Trials for emb-01

Emb-01 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating emb-01, 1 is phase 1/phase 2 (1 open).

EGFR Mutation and MET Mutation are the most frequent biomarker inclusion criteria for emb-01 clinical trials.

Malignant solid tumor and non-small cell lung carcinoma are the most common diseases being investigated in emb-01 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Emb-01
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating emb-01 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
emb01
Drug Target(s) [2]:
EGFR, MET

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.